335results about "Library screening" patented technology

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

The invention provides a nucleic acid aptamer and a screening method thereof, the aptamer is of an oligonucleotide DNA structure, the nucleotide sequence of the nucleic acid aptamer is the nucleotide sequence of any DNA fragment as shown in SEQ ID NO: 1-9, and the nucleic acid aptamer can specifically target cardiac muscle cells (CMs). According to the invention, a new strategy can be provided for clinical treatment of cardiovascular diseases, and meanwhile, bioactive molecules such as microRNA (miRNA), small interfering RNA (small interfering RNA, siRNA), lipidosome, microspheres, microcapsules and the like can be carried to be used as an intracellular drug delivery tool.

An automated high throughput screening platform for identification of compounds and genomic constructs having mitochondrial function modulating activity and compounds so identified are provided. Use of such compounds for modulating mitochondrial function are also disclosed. A high-throughput screening method of determining genetic mechanisms of action for therapeutic or toxic agents in genetic or pharmacologic models of disease are also provided.

Methods for preparing a personalized cancer vaccine and a method to train a machine learning HLA-peptide presentation prediction model. Further wherein, a method of making a HLA class II tetramer or multimer comprising an epitope, the method comprising contacting a purified soluble HLA-DM loaded with a peptide epitope with a HLA class II tetramer or multimer, thereby forming a HLA class II tetramer or multimer loaded with the peptide epitope, is disclosed.

A genetic prime editing screening platform to identify functional variants related to human health and disease, is configured substantially to annotate genome with nucleotide resolution with actionable disease prediction and treatment for personalized medicine.

A method for analyzing macromolecules, including peptides, polypeptides, and proteins, employing nucleic acid encoding is disclosed.

Protease activity can be assessed using a microfluidic system that comprises a microfluidic device and solid support, wherein the solid support comprises a protease fusion protein bound to a first surface of the solid support; wherein the protease fusion protein comprises a protease domain, a protease activation sequence, and a fluorescent protein tag, wherein the fluorescent protein tag is bound to the protease domain and to the first surface of the solid support. Protease activity can be assessed in a microfluidic system by reacting an activating protease with a protease fusion protein; wherein the protease fusion protein comprises a protease domain and a protease activation sequence; wherein the activating protease cleaves the protease activation sequence, thereby activating the protease domain in the protease fusion protein to produce an activated protease fusion protein; reacting the activated protease fusion protein with a detectable substrate, thereby generating a detectable signal; and detecting the detectable signal, thereby detecting protease activity in the microfluidic system.

The invention provides methods for determining aneuploidy and / or fetal fraction in maternal samples comprising fetal and maternal ctDNA by massively parallel sequencing. The method comprises a novel protocol for preparing sequencing libraries that unexpectedly improves the quality of library DNA while expediting the process of analysis of samples for prenatal diagnoses.

Provided herein are compositions comprising a particle comprising a library encoded bead (e.g., DEL bead) coated in a polymeric matrix forming a core-shell particle, wherein the core-shell particle is further inside a 3D tissue culture. Also provided herein are methods of making such particles, and methods of using such particles for drug discovery such as identification of bioactive compounds via high-throughput cellular activity-based phenotypic screens of DNA-encoded chemical library beads.

The disclosure relates to novel soybean plants, plant parts, and nucleotide sequences in soybean plants comprising an amorphic allele of a RPF1 gene, along with methods of using and making the same.

The present application provides detection and prognosis of infectious diseases. In particular, the present application provides fragment length profiles of nucleic acid libraries, methods of generating fragment length profiles of nucleic acid libraries, and methods of using the fragment length profiles for diagnosis and / or prognosis. The present application further provides methods, compositions, and kits for determining the stage or site of infection in a subject.

Provided herein are compositions and methods of modulating myeloid cell-mediated killing of cancer cells and modulating the activity of myeloid cell immune checkpoint inhibitors. Also provided herein are methods of screening for modulators of myeloid cell-mediated killing of cancer cells and modulators of myeloid cell immune checkpoint inhibitors.

Provided herein are methods for generating circular nucleic acid molecules and circular nucleic acid libraries. The methods can be used to generate clonal populations of target nucleic acid molecules

The present invention relates to a method for preparing a highly concentrated monoclonal antibody (mAb) formulation, comprising screening and selection of excipients to be included in the mAb formulation. The excipients include amino acids, salts, and polyols.

The present invention provides a method of constructing a library of binder scaffolds (library of protein scaffolds) comprising the steps a) providing an initial polypeptide, wherein said initial polypeptide comprises or consists of a polypeptide having at least 90% identity to SEQ ID NO:1, and b) introducing diversity into copies of said initial polypeptide to form the binder scaffold library (protein scaffold library).

Metastasis is a major cause of fatality and expense in cancer. Many metastatic patients express calcified, fibrotic, or deep-seated (lymph / Jung / brain) lesions that are not easily profiled. For such patients, decision-making regarding treatment selection is population-based and heavily reliant on standards of care and are not tailored to the individual's tumor. The present disclosure provides methods of identifying treatment protocols for cancer patients using released tumor cells (RTCs). Method described herein include isolating / enriching RTCs, profiling RTCs and comparing RTCs to reference RTC profile libraries.

An oligopeptide has the amino acid sequence of Thr-Val-Asp-Ser-Cys-Leu-Thr (SEQ ID NO: 1) with addition or insertion of a (poly)peptide to the oligopeptide, or substitution of a (poly)peptide for a part of amino acids of the oligopeptide.

The present invention relates to methods for efficiently generating recombinant monoclonal antibodies derived from B cells of a non-human host which has been immunochallenged with one or more target antigens. The methods comprise the steps of identifying and isolating B cell that bind to the antigen by FACS, and recombining and enriching for thousands of cells to create a B cell library. Related products and methods, such as methods of producing expression libraries, are also disclosed.

The present disclosure provides base editor fusion proteins, complexes, and systems capable of installation of multiple edits across large genomic windows (e.g., between 4bps and 500 bps) and which may be useful, for example, for mutating one or more nucleotides in a target nucleic acid. The disclosure describes gene editing systems comprising a first fusion protein comprising a C-terminal portion of a split deaminase and a first epitope binding domain, a second fusion protein comprising a N-terminal portion of a split deaminase and a second epitope binding domain, and a third fusion protein comprising a DNA binding protein domain and one or more epitope domains to which the first and second fusion proteins may bind (along the one or more epitope domains), thereby forming an active deaminase domain. The base editor fusion proteins, complexes and systems can be used in certain embodiments in methods of performing mutational screens in a gene of interest. Other aspects of the disclosure relate to methods, for example, methods of mutating one or more nucleotides in a target nucleic acid and methods of performing mutational screens. The disclosure also provides compositions, polynucleotides, vectors, pharmaceutical compositions, cells, kits, and systems comprising the base editor fusion proteins and complexes contemplated herein.

The invention relates to the technical field of biological medicines, in particular to a polypeptide targeting B cell lymphoma cells, a targeting effect conjugate and application of the polypeptide and the targeting effect conjugate. Wherein the peptide chain length of the polypeptide targeting the B-cell lymphoma cells is 12 amino acids, and the polypeptide is selectively and specifically combined with the B-cell lymphoma cells. The targeting effect conjugate is formed by connecting polypeptide and pro-apoptotic peptide through a connecting peptide. The pro-apoptotic peptide can induce programmed death of target cells by destroying a mitochondrial membrane structure. The molecular weight of the polypeptide is small, the chemical synthesis process is simple, convenient and efficient, high consistency between different batches of products can be ensured in the synthesis process, and a guarantee is provided for subsequent quality control. The small molecular structure is also convenient for sequence optimization and terminal modification, can create extremely favorable conditions for subsequent structure-function relationship research and pharmaceutical development work, and is helpful for accelerating the research and development process of novel therapeutic drugs.

The present invention relates to methods for producing recombinant binding proteins with binding specificity for peptide-MHC (pMHC) complexes. The invention also relates to recombinant binding proteins with binding specificity for pMHC complexes, which comprise one, two or more designed repeat domains, preferably designed ankyrin repeat domains, and to such binding proteins which further comprise a binding factor with binding specificity for a protein expressed on the surface of immune cells, preferably T cells. In addition, the invention relates to nucleic acids encoding such binding proteins or repeat domains, pharmaceutical compositions comprising such binding proteins or nucleic acids, and the use of such binding proteins, nucleic acids or pharmaceutical compositions in methods for treating or diagnosing diseases, including cancer, infectious diseases and autoimmune diseases.

Precursors for forming a plurality of multielement materials of different compositions can be deposited on different portions of a common substrate according to a combinatorial approach. The substrate can be subjected to a thermal shock, thereby converting the deposited precursors into separate multielement materials on the substrate. The thermal shock can be a temperature greater than or equal to 500° C. and a duration less than 60 seconds. In some embodiments, each multielement material can be tested with respect to an electrical property, a chemical property, or an optical property. Based on the results of the testing, a composition of a multielement material can be determined for use in a predetermined application, such as use as a catalyst, a plasmonic nanoparticle, an energy storage device, an optoelectronic device, a solid-state electrolyte, or an ion conductive membrane.

The invention relates to ribozyme for labeling biotin on target RNA (Ribonucleic Acid) as well as a screening method and application thereof. The RNA labeling technology is one of core tools for modern molecular biology research and clinical diagnosis. A specific marker is covalently linked to a target RNA molecule, so that accurate tracking, efficient detection and functional analysis of RNA can be realized. A biotin-streptavidin system becomes one of the technical routes which are most widely applied due to extremely high affinity and signal amplification capability of the biotin-streptavidin system. At present, common biotin-labeled RNA technical methods mainly comprise a chemical solid-phase synthesis method, an enzymatic method and a chemical labeling method. However, the methods have the limitations of poor site specificity, low efficiency, complex manipulation and the like in the use process. The engineering ribozyme for catalyzing RNA biotinylation is obtained by taking 12: 0 biotin coenzyme A as a biotin donor through an in-vitro screening technology. The ribozyme provided by the invention can efficiently and specifically carry out biotin labeling on target RNA, the reaction process is simple, and the labeling activity is up to 90% or above.

The invention relates to methods of identifying enzymes and methods of screening for optimised enzymes for degrading polymers such as plastics. The invention also relates to polymer degrading enzymes and nucleic acids encoding these enzymes as well as expression cassettes and host cells comprising the nucleic acids. The invention also relates to uses of these enzymes or the host cells comprising the nucleic acids encoding these enzymes to degrade polymers such as plastics. Lastly, the invention also relates to the crystal structure of plastic degrading enzymes and uses of these structures.

The invention provides a pilot small-molecule compound and application thereof, the structural formula of the pilot small-molecule compound is shown in the specification, and application of the small-molecule compound in preparation of a preparation for inhibiting FGL2 activity. The pilot small molecule compound provided by the invention can be combined with FGL2 protein to play a role in inhibiting the FGL2 protein, so that the development process of tumors is slowed down.

An object of the present invention is to provide a therapeutic or preventive agent for myocardial infarction, cardiac fibrosis, or heart failure using Htra3 as a therapeutic target. According to the present invention, there is provided a therapeutic or preventive agent for myocardial infarction, cardiac fibrosis, or heart failure containing at least one of (a) serine protease HtrA3, (b) a nucleic acid encoding HtrA3, (c) an expression vector containing a nucleic acid encoding HtrA3, (d) a cell transformed with the nucleic acid or the expression vector, and (e) an antibody that binds to serine protease HtrA3.

Provided herein are direct-to-library methods, systems, and compositions.

The invention relates to a new method for selecting or screening antibodies and antigens from an antibody library together with suitable expression vectors and their use.